Introduction
============

Australia is a federation of six States and two territories with a national (Commonwealth) government In 2003, the population was just over 20 million, mostly concentrated on the eastern side of the continent.

Australia has a mixed government and private health care system. In 2000-2001, they spent approximately 9 percent of its gross domestic product on health services---70 percent by the government and 7 percent mediated by private health insurance organizations and the remainder by other arrangements, including private out-of-pocket costs. There is a universal health insurance arrangement that provides government rebates for the costs of private medical practice and for stays in public hospitals. Approximately 45 percent of the population has private health insurance covering the costs of stays in private hospitals. Persons taking out private health insurance are eligible for a government rebate of 30 percent of the cost of that insurance. The third element of government protection against health costs is in the form of the PBS that predated the major expansion of government support for hospital and medical care. Expenditure on pharmaceuticals is 12.4 percent of total health expenditure and 14.1 percent of government health expenditure. In 2000, Australia spent approximately \$292 per person, per year on pharmaceutical services (adjusted to U.S. dollars using purchasing parities), compared with U.S. expenditure of \$541 per capita ([@b34-hcfr-25-3-055]).

Taking a prescription or non-prescription medication is the most common health care activity among Australians. Australian Health Survey data show that almost 70 percent of the population used some form of medication 2 weeks prior to the interview ([@b2-hcfr-25-3-055]). The most common forms of medication usage was vitamins or minerals (258 persons per 1,000).

The second most common form was in pain relievers (236.2 persons per 1,000) followed by heart problems or blood pressure medications (105.8 persons per 1,000). Use of these medications is not necessarily preceded by any form of medical or other health professional advice, and many of these medications (e.g., vitamins and herbal medications) do not have any form of government rebate.

Over two-thirds of doctor visits involve recommendations about medication, most of which result in a prescription drug ([@b6-hcfr-25-3-055]), 38.7 percent involved one, 13.6 percent involved two, 7.5 percent more than two, and 40.2 percent involved no prescription.

Australia has adopted a National Medicines Policy to guide policy development of pharmaceuticals ([@b14-hcfr-25-3-055]). Key elements are:

-   Timely access to the medicines that Australians need, at a cost to individuals and the community can afford.

-   Medicines meeting appropriate standards of quality, safety, and efficacy.

-   Quality use of medicines.

-   Maintaining a responsible and viable medicine industry. (Commonwealth Department of Health and Aged Care, 1999).

The principal mechanism for ensuring access to medicines is the PBS. Quality, safety, and efficacy of medicines are regulated through the Therapeutic Goods Administration, with policies and processes similar to the United States\' Food and Drug Administration. Quality use of medicines involves a range of policies in terms of educational programs, consumer information, etc. The responsible and viable medicines industry component is achieved through the pharmaceutical industry support program. This article reviews and outlines Australia\'s policies for ensuring access and promoting quality use of medicines.

Ensuring Access
===============

The PBS was introduced on July 1, 1948, but relatively few prescriptions were covered under it because of opposition from the medical profession. The new (conservative) government elected in 1949 revised the PBS on September 4, 1950, introducing a list of 139 "life saving and disease preventive drugs" that were provided free of charge to the entire community ([@b43-hcfr-25-3-055]). Since then, the range of drugs covered by the PBS has increased dramatically and by August 2003, it covered 601 generic products, available in 1,469 forms or strengths, and marketed as 2,602 different brands. Some of these items are restricted, requiring some form of preauthorization to prescribe them (over and above medical registration). Obtaining this preauthorization requires contact with the administering agency of the PBS, the Health Insurance Commission and may, for example, require the medical practitioner to certify that specific indications for prescribing the medication are present. Obtaining authorization is not well received by doctors and is seen as bureaucratic and not evidence based ([@b21-hcfr-25-3-055]).

The major types of drugs prescribed under the PBS are shown in [Table 1](#t1-hcfr-25-3-055){ref-type="table"}. Drugs are grouped using the Anatomical Therapeutics Chemical Code (ATC). There are five levels to the ATC: anatomical main group, therapeutic main group, therapeutic subgroup, chemical/therapeutic subgroup, and generic drug name.

The most frequently prescribed group of drugs are those for the cardiovascular system, accounting for just over 30 percent of all prescriptions and costs. Twenty percent of both prescriptions and costs are for the nervous system. Antineoplastic and immunomodulating agents, although accounting for less than 1 percent of prescriptions, account for 6 percent of costs. These cost, on average, ten times as much as the average drug dispensed under the PBS.

The PBS initially required no patient copayment, then on March 1, 1960, a 50-cent copayment was introduced for general beneficiaries under the PBS. A copayment for pensioners of A\$2.50[^1^](#fn2-hcfr-25-3-055){ref-type="fn"} per prescription was introduced on November 1, 1990. The copayment amounts are indexed for inflation and, by 2003, the copayment for pensioners had increased to A\$3.70 per prescription and for general beneficiaries to A\$23.10. The PBS provides some protection from the cumulative impact of these copayments through a safety net threshold that is set for pensioners at 52 times the copayment. If pensioners require more than 52 prescriptions in any one CY, they can obtain a safety net card that entitles them to further prescriptions without any copayment. The safety net threshold for general beneficiaries applies after they (or their immediate family) purchase PBS items that total a copayment of at least A\$708.40 in any CY, after that, prescriptions are supplied for the concessional copayment.

Where a pharmaceutical is listed on the PBS under more than one brand name, pharmacists may dispense generic forms of the drug unless specifically directed not to do so by the prescribing medical practitioner on the prescription form. If generic equivalents are available, the PBS will only pay for the least-costly product and the consumer pays any additional costs for a specific brand-name alternative in addition to the copayments previously discussed. This brand name equal is not counted as part of the safety net arrangements. An additional alternative is also payable if other pharmaceuticals in the same therapeutic class are deemed to be equivalent, and an exemption on clinical grounds has not been granted for that patient. This policy (known as Therapeutic Group Premiums) applies only to items in three therapeutic groups: H2-receptor antagonists; calcium channel blockers; and ACE inhibitors.

The generic substitution policy is facilitated by a government requirement that, where computer software used by medical practitioners to generate prescriptions for the PBS has a default preferred drug, it defaults automatically to the generic form of a drug rather than a proprietary form of the drug. As of May 2002, 293 products had a brand premium, with the premium ranging from 1 cent to A\$79.48. Over 30 million prescriptions had been dispensed with a brand-premium, being about 50 percent of all prescriptions covered by the brand-name premium policy ([@b23-hcfr-25-3-055]).

[Figure 1](#f1-hcfr-25-3-055){ref-type="fig"} shows the growth in pharmaceutical benefits expenditure since the inception of PBS. Expenditure on pharmaceutical benefits has increased exponentially since the beginning of the program, with particularly rapid growth in expenditure on drugs used by pensioners and concessional cardholders. More importantly, 73 percent of government pharmaceutical benefits prescription expenditure is for pensioners, severely limiting the ability of government to curtail expenditure using the strategy of shifting costs to consumers. People age 65 or over have a 50-percent higher prescription rate than those under age 45. This high percentage of use for pensioners should not be surprising because the elderly generally have poorer health status than younger persons and have higher hospital utilization rates.

Expenditure on pharmaceuticals has been growing faster than the economy as a whole in recent years. Since the late 1970s, pharmaceutical expenditure has grown from 0.6 percent of gross domestic product to 1.1 percent in 2000-2001. For most of the last decade patient contributions, which account for 15 percent of the PBS expenditure, have been increasing at 5 to 8 percent per year in real terms. Government expenditure has been increasing faster than this at 7 to 14 percent per year. This growth in expenditure is partly driven by increased utilization and by increased prices for dispensed medications.

Expenditure on the PBS is the fastest growing component of health expenditure, growing at 15- to 20-percent per year. If the current rates of growth continue, expenditure on the PBS will exceed that on public hospitals by 2007-2008 and on all hospitals by 2010-2011 ([@b45-hcfr-25-3-055]).

Growth in expenditure is distributed unevenly across the PBS with use of newer drugs increasing faster than older drugs. The average price of a new drug listed on the PBS is about two times that of all drugs on the PBS ([@b44-hcfr-25-3-055]).

For most of the last decade, the growth in PBS expenditure has primarily been driven by increases in the number of prescriptions that had been listed on the schedule for at least 12 months rather than by the cost of new drug listings ([@b44-hcfr-25-3-055]). For the last 5 years, price effects of drugs that have been listed for more than 12 years have acted to moderate growth in expenditure rather than contribute to it.

The decision to list an item on the PBS can lead to commitment of significant government expenditure, and since 1993 has involved a decision not only about whether the drug is an effective complement to existing items on the PBS, but also an assessment of whether the drug is cost effective. The legislation to require cost-effectiveness analysis was passed in 1987; draft guidelines on how listing submissions were to incorporate cost-effectiveness analysis were published in 1990, with definitive guidelines in 1992. (These guidelines are updated regularly on <http://www.health.gov.au/pbs/general/pubs/guidelines> \[accessed 2004\]).

The guidelines provide that a drug will be listed on the PBS if it is:

-   Needed for the prevention or treatment of significant medical conditions not already covered, or inadequately covered, by drugs in the existing list and is of acceptable cost effectiveness.

-   More effective, less toxic (or both) than a drug already listed for the same reasons and is of acceptable cost effectiveness.

-   At least as effective and safe as a drug already listed for the same reasons and is similar or shows more cost effectiveness.

Under the cost-effectiveness arrangements, the pharmaceutical manufacturer needs to present cost-effectiveness data, usually based on randomized controlled trial evidence against a designated comparator, to the Pharmaceutical Benefits Advisory Committee (PBAC) ([@b15-hcfr-25-3-055]; [@b13-hcfr-25-3-055]; [@b12-hcfr-25-3-055]; [@b17-hcfr-25-3-055]; [@b38-hcfr-25-3-055]; [@b28-hcfr-25-3-055], [@b19-hcfr-25-3-055]). A retrospective study of the decisionmaking process showed that new pharmaceuticals costing more than A\$68, 913 for each life year saved are generally not listed on the PBS, while those costing less than A\$36, 450 for each life year saved are listed. No apparent decision rules have been found to apply to the intermediate zone ([@b10-hcfr-25-3-055]).

The operation of PBAC and the economic evaluation policies of the PBS have not been entirely without problems or controversy. Almost two-thirds of submissions to PBAC have contained significant problems from the point of view of the PBAC evaluators, most of which were seen as avoidable ([@b19-hcfr-25-3-055]).

In a controversial move early in 2001, the government restructured the membership of PBAC to include a person with strong industry links. This initiative was believed to be in response to industry pressure to water down the strong emphasis on economic evaluation followed by PBAC and was seen in the public debate as weakening PBAC ([@b11-hcfr-25-3-055]). These fears do not appear to have translated into reality and economic evaluation still appears to be a central component of the listing decisions ([@b1-hcfr-25-3-055]).

As part of the listing decision, the government establishes a price for the drug after advice from the Pharmaceutical Benefits Pricing Authority (PBPA). In determining the price, the PBPA takes into account:

-   The PBAC comments on clinical and cost effectiveness.

-   Prices of alternative brands of a drug.

-   Comparative prices of drugs in the same therapeutic group.

-   Cost information, whether provided by the supplier or estimated by the PBPA.

-   Prescription volumes, economies of scale, and other factors such as date expiration, storage requirements, product stability, and special manufacturing requirements.

-   Prices of the drug in relevant overseas countries.

The Australian Orphan Drug Program provides support for registration and listing of new therapeutic agents for rare diseases through waived application fees. The purchasing arrangements for pharmaceuticals covered under the PBS involve a government agreed-upon price (90 percent of which is for the supplier, and 10 percent for the wholesaler). The government also undertakes postmarketing surveillance to ensure that the volumes of listed drugs are close to those predicted in the cost-effectiveness analyses and other submissions on which the pricing negotiations were based.

Historically, the government has been able to use its monopsonistic purchasing strength to achieve lower prices relative to those paid in international markets. The ability to do this appears to be weakening as other countries establish schemes similar to the PBS and monitor international pricing negotiations ([@b22-hcfr-25-3-055]). However, [@b4-hcfr-25-3-055] have documented an example where the market price rose when the product was deleted from the PBS.

The pharmaceutical industry is regularly ranked as the most profitable of all industries and pricing decisions of the PBS have significant implications for profit that pharmaceutical manufacturers obtain from selling their products in Australia. One of the major costs of bringing a drug on the market are in the research and development that can occur over a long period of time. Of course, research and development costs associated with failed research or research that does not lead to a drug that comes on to the market needs to be spread over the costs of pharmaceuticals which do come on to the market. In many cases the drug research is subsidized by national research organizations, such as the National Health and Medical Research Council.

International comparison of pricing is difficult, in part because of the existence of discounting arrangements in several countries: list prices may not reflect prices actually paid in the market place ([@b35-hcfr-25-3-055]). Accordingly, in its major study of comparative prices of drugs, the Productivity Commission reported high and low estimates of the difference between costs in other countries and costs in Australia ([Figure 2](#f2-hcfr-25-3-055){ref-type="fig"}). The high estimate is the greatest difference likely to be found.

There are a number of broad, general conclusions that can be drawn from [Figure 2](#f2-hcfr-25-3-055){ref-type="fig"}. Prices in Australia are certainly substantially less than prices in the U.S. On the other hand, prices in Australia are similar to prices in other countries. The success of the PBS in restraining prices has attracted the attention of the U.S. pharmaceutical manufacturing industry ([@b25-hcfr-25-3-055]). However, listing on the PBS reduces the effective price faced by consumers, and hence economic theory would predict that it is likely to lead to increased demand and sales against a situation of unsubsidized prices. This in turn suggests that even with the relatively lower prices paid by the PBS, pharmaceutical manufacturers may be better off because of the increased sales than they would be in the absence of the PBS ([@b46-hcfr-25-3-055], [@b47-hcfr-25-3-055]).

There are significant differences in price relativities for different types of drugs. The differences between new and innovative pharmaceuticals are much lower than for all pharmaceuticals suggesting that the Australian purchasers (particularly those involved in setting prices under the PBS) are not able to extract the same price discounts for newer drugs relative to older drugs.

Because listing under the PBS provides a significant marketing boost (by reducing the effective price faced by consumers to the copayment), the government is in a strong position to negotiate over price. However, where a pharmaceutical company has a new medication significantly superior to others, or which is unique, it can threaten to rely on consumers paying the full price for the drug rather than accept a lower price from the government. In these circumstances, consumers are likely to place significant pressure on the government to list the product.

Quality Use of Medicines
========================

The fourth arm of National Medicines Policy is to promote the quality use of medicines. Although such a policy could involve a mix of strategies, the emphasis in Australia has been on sporadic educational programs rather than systematic use of incentives on manufacturers or medical practitioners. Such campaigns encourage consumers to be more judicious in use of medication and/or attempt to educate medical practitioners to reduce their prescribing. The high rate of growth in the cost of pharmaceuticals has led the government in Australia (and around the world) to develop a number of strategies to limit this expenditure ([@b39-hcfr-25-3-055]; [@b27-hcfr-25-3-055]). [Table 2](#t2-hcfr-25-3-055){ref-type="table"} shows some of the strategies that have been utilized in Australia.

In broad general terms, the government can shape pharmaceutical policy by intervening at any point of the drug distribution chain with initiatives targeted at manufacturers, medical practitioners who prescribe drugs, pharmacists who dispense drugs, and consumers.

Different policy initiatives will have different equity effects and will have different impacts. Policies to reduce consumption of pharmaceuticals could involve a mix of price strategies on the demand side, increasing consumer copayments or, alternatively, acting on supply by attempting to change the behavior of manufacturers by reducing the incentives to manufacturers to promote increased use of pharmaceuticals. One of the most powerful supply-side strategies is using price volume contracts to reduce the price paid under the PBS as volume increases. The two different strategies have different equity impacts and different effectiveness. Organizational and systemwide change by changing incentives on the manufacturers will have a far more pervasive effect than educational strategies on medical practitioners.

Despite the regulation of claims made by pharmaceutical manufacturers in their advertising campaign to medical practitioners, manufacturers advertising to medical practitioners do not promote the scientific basis of their products ([@b24-hcfr-25-3-055]). Because there are few price volume agreements in place under the PBS, manufacturers have a very strong incentive to increase sales when the marginal cost production of the additional drugs is well below the revenue from the PBS. These incentives on manufacturing companies overwhelm the educational campaigns on medical practitioners. Pharmaceutical marketing budgets are large and this results in entanglement between doctors and the manufacturing companies as the manufacturers encourage medical practitioners to prescribe their products through enticements ([@b30-hcfr-25-3-055]). Manufacturing companies also support consumer organizations to lobby for inclusion of relevant drugs on the PBS and use the consumer organizations to advocate use of the manufacturer\'s product ([@b16-hcfr-25-3-055]).

The primary interest of the pharmaceutical industry is in maximizing sales and profits, and in Australia this usually translates into maximizing government expenditure. Australia uses a range of strategies to rein in pharmaceutical benefits expenditure, for example, providing feedback to general practitioners on costs ([@b3-hcfr-25-3-055]; [@b18-hcfr-25-3-055]; [@b14-hcfr-25-3-055]; [@b32-hcfr-25-3-055]). Despite government programs to promote evidence-based prescribing and improve consumer information ([@b42-hcfr-25-3-055]), the pharmaceutical industry has been remarkably successful in creating needs ([@b31-hcfr-25-3-055]), persuading medical practitioners to prescribe the latest drug, even if benefits to the consumer are marginal and practitioners do not profit directly from increased sales to their patients ([@b29-hcfr-25-3-055]; [@b8-hcfr-25-3-055]; [@b37-hcfr-25-3-055], [@b36-hcfr-25-3-055]).

An important contributor to Australia\'s quality use of medicines strategy is the government-funded National Prescriber Service (NPS) (<http://www.nps.org.au>) which provides evidence-based information to health providers and consumers about medicines, ostensibly independently of industry and government. But even this independent service can be subject to government and/or industry conniving, with government recently asking the NPS not to educate doctors about two newly listed diabetes medications ([@b26-hcfr-25-3-055]).

Supply Arrangements
===================

Payments to pharmacists for dispensing prescriptions under the PBS are set following negotiations between the Commonwealth government and the Pharmacy Guild of Australia. The contemporary arrangements are incorporated in the Third Community Pharmacy Agreement for the 5-year period from July 1, 2000, to June 30, 2005 (<http://www.health.gov.au/pbs/healthpro/pharmacy/pharmacyagree.pdf>. The agreement provides for differential base dispensing fees for dispensing ready prepared items (A\$4.40 fee in 2000-2001) and extemporaneously prepared items (A\$6.28). In either case the pharmacist also receives a markup of 10 percent on the agreed-upon price if that price is less than A\$180, A\$18 if the price is between A\$180 and A\$450, and 4 percent if the price is more than A\$450. The base fees are indexed annually. The agreement also provides for upward or downward adjustment of payments if the average markup increases by more than 4 percent over that projected in the agreement of if prescriptions increase faster or slower than projected. The operation of these claw-back and supplementation arrangements both protect the government from additional expenditure on pharmacists simply because of increases in average prescription prices and protects pharmacists from the impact on total remuneration if prescription volume declines. The agreement also provides that pharmacists can receive a range of other miscellaneous fees and allowances.

Evaluation of The PBS
=====================

Australia\'s arrangements for the supply of pharmaceuticals are the envy of many other developed countries. The PBS performs well in terms of criteria of equity, efficiency, quality, and acceptability. In terms of equity, the structure of the PBS minimizes the financial barriers to access to pharmaceuticals. The low copayment for concession cardholders ensure that they have access to the medication prescribed for them: only 2 percent of people age 65 or over have reported that they did not fill a prescription because of cost ([@b40-hcfr-25-3-055]). However, copayments for the general population are much higher than for concession cardholders, and may create a barrier, especially for people with low incomes. [@b5-hcfr-25-3-055] has reported that 23 percent of Australians did not fill a prescription because of cost.

In terms of efficiency, the PBS again performs well in the sense that all new drugs are subject to economic evaluation prior to listing. Because new drugs listed on the PBS have been evaluated for their cost effectiveness, it could be argued that any increased expenditure on the PBS is worthwhile in terms of savings in other sectors of the health care industry (for example, hospitals), in increased productivity (reduced time off work), or in terms of improved quality of life generally. Thus, even where there is increased expenditure on these drugs, this may be efficient and cost effective when viewed in a wider economic context.

The success of the cost-effectiveness strategy relies on rigorous standardized cost-effectiveness analyses undertaken in accordance with published guidelines. It also relies on ensuring that pre-listing estimates of demand (based on the indications tested in the cost-effectiveness analyses) hold true once the drug is marketed. However, pharmaceutical companies are normally the sponsors of cost-effectiveness analyses submitted for review. [@b9-hcfr-25-3-055] and [@b33-hcfr-25-3-055] have shown that drug company funded cost-effectiveness analyses are more likely than studies funded from other sources to report favorable cost-effectiveness results. There is also a tendency for drug company sponsored studies to overstate qualitative conclusions (that is, a favorable qualitative conclusion in the face of neutral or negative quantitative results). Studies sponsored by pharmaceutical manufacturers are also more likely to report outcomes favoring the sponsor than research funded from other sources ([@b20-hcfr-25-3-055]).

The Commonwealth government\'s Department of Health and Ageing undertakes post-marketing surveillance of new PBS listings, but renegotiation of prices in the face of unexpected increased sales volumes is relatively unusual. A weakness of the PBS in terms of efficiency lies in this area of post-market surveillance: the economic evaluation is based on a particular range of conditions and evidence from particular research studies, and that prescription use of the drug in practice, and its promotion by the manufacturers may not be in accordance with the research and the basis of the listing decision. Efficiency of the scheme would be promoted if there were stronger incentives on manufacturers to restrain use in line with the research evidence, possibly by expanded use of pricing arrangements.

Although the PBS incorporates incentives for the quality use of medicines, the incentives are primarily directed at the weakest points of the supply chain in terms of the effectiveness of policy instruments. Educational strategies aimed at consumers and medical practitioners should be supplemented by stronger incentives on manufacturers to encourage quality use of medicines. Evidence of over-prescription can be seen in the rate of admissions to hospitals for drug-related adverse events.

Finally, the PBS appears to be popular and so would rate highly in terms of the criterion of acceptability. As almost 80 percent of pharmaceutical benefits expenditure is for pensioners and concessional beneficiaries, the program is already highly targeted. As a corollary, in 1989-1990, 26 percent of persons in the lowest income decile benefited from the PBS subsidy for pharmaceuticals compared with 5 percent of persons in the highest income decile ([@b41-hcfr-25-3-055]). Further use of demand side strategies, such as patient copayments, would thus have an adverse impact on equity, but this effect has not precluded advocacy of this policy option, especially by pharmaceutical manufacturers ([@b22-hcfr-25-3-055]). It should therefore be anticipated that expenditure on the PBS will continue to rise as new therapeutic agents are developed and replace older, less expensive products.
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![Ratio of Prevailing Prices for Pharmaceuticals in Selected Countries in Comparison to Australia\'s^1^ Pharmaceutical Benefits Scheme: 2000\
^1^ PBS equals 1.0. NOTE: Me-too pharmaceuticals are pharmaceuticals for which an alternative is already available.\
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###### Number, Total Cost, Average Price, and Percent Change of Prescriptions Issued under Australia\'s Pharmaceutical Benefits Scheme, by Anatomical Therapeutics Chemical Code: July 1, 2000, to June 30, 2002

  Code                                                     Year Ended June 30, 2002   Percent Change 2000 to 2002                          
  -------------------------------------------------------- -------------------------- ----------------------------- -------- ------ ------ ------
  Total                                                    154,970,262                5003.3                        32.29    4.7    9.6    4.7
  Alimentary Tract and Metabolism                          19,082,701                 692.4                         36.28    6.4    7.4    0.9
  Blood and Blood Forming Organs                           4,023,864                  111.9                         27.8     12.3   38.5   23.3
  Cardiovascular System                                    46,587,011                 1556.9                        33.42    5.3    8.7    3.2
  Dermatologicals                                          2,934,367                  81.2                          27.68    -2.7   1.1    3.9
  Genito Urinary System and Sex Hormones                   6,323,714                  159.8                         25.27    2.7    20.4   17.3
  Systemic Hormonal Preparations, Excluding Sex Hormones   2,304,729                  30.2                          13.09    3.9    8.1    4.0
  General Anti-Infectives for Systemic Use                 12,550,089                 273.1                         21.76    -1.1   2.9    4.0
  Antineoplastic and Immunomodulating Agents               961,818                    317.7                         330.35   8.0    17.2   8.5
  Musculo-Skeletal System                                  10,709,738                 340.1                         31.75    27.2   14.4   10.0
  Nervous System                                           30,564,051                 906.5                         29.66    3.4    8.6    5.1
  Antiparasitic Products, Insecticides and Repellants      910,580                    8.9                           9.81     0.4    2.4    2.0
  Respiratory System                                       10,341,286                 374.0                         36.16    -6.5   7.3    14.8
  Sensory Organs                                           6,779,904                  104.0                         15.33    4.4    8.1    3.6
  Various                                                  602,127                    43.6                          72.41    5.7    5.4    -0.3
  Not Otherwise Classified                                 294,283                    3.1                           10.58    -6.5   0.0    6.9

SOURCE: Duckett, S.J.: estimates derived from <http://www.hic.gov.au/statistics/dyn_pbs/forms/pbsgtab1.shtml> (Accessed 2004.)

###### Targets for Control of Government Pharmaceutical Expenditure Used in Australia

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
           Demand                                                                              Supply
  -------- ----------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Price    Patient co-payments. Encourage prescription of "generic" (non-brand name) drugs.\   Negotiate prices based on lowest in other countries.
           Encourage prescription of alternative medication in same therapeutic class.         

  Volume   Patient education programs.                                                         Incentives on medical profession as a whole to limit prescribing.\
                                                                                               Practice guidelines.\
                                                                                               Limit inclusion on the approval list through use of cost effectiveness analysis.\
                                                                                               Provide education program to pharmacists, doctors.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SOURCE: Stephen J. Duckett, M.H.A., Ph.D., La Trobe University, Victoria, Australia, 2004.
